 Objective responses tumor reduction observed in 83 5 of 6 of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63 5 of 8 of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Objective responses tumor reduction observed in 83 5 of 6 of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63 5 of 8 of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy 